Amicus Therapeutics (FOLD) : Traders are bullish on Amicus Therapeutics (FOLD) as it has outperformed the S&P 500 by a wide margin of 5.85% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 10.89%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 11.49% in the last 1 week, and is up 3.7% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 4.7% and the 50-Day Moving Average is 9.73%.The 200 Day SMA reached 1% Amicus Therapeutics, Inc. is up 29.54% in the last 3-month period. Year-to-Date the stock performance stands at -24.95%.
Amicus Therapeutics (FOLD) stock is expected to deviate a maximum of $3.72 from the average target price of $13.33 for the short term period. 6 Street Experts have initiated coverage on the stock with the most promising target being $19 and the most muted being $9.
For the current week, the company shares have a recommendation consensus of Buy. Amicus Therapeutics (NASDAQ:FOLD): The stock opened at $7 and touched an intraday high of $7.32 on Friday. During the day, the stock corrected to an intraday low of $6.9, however, the bulls stepped in and pushed the price higher to close in the green at $7.28 with a gain of 2.97% for the day. The total traded volume for the day was 3,772,183. The stock had closed at $7.28 in the previous trading session.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.